{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002784","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.828850+00:00","generated_at":"2026-06-02T02:31:12.060598+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Compass Therapeutics Q1 net loss $10.8M; cash $156.3M; FDA Fast Track for CTX-009","bullets":["Net loss $10.8M ($0.08/share) vs $7.8M ($0.06) in Q1 2023; R&D expenses rose to $9.5M.","Cash and marketable securities $156.3M at March 31, 2024; cash runway into late 2026.","FDA Fast Track for CTX-009 in BTC; COMPANION-002 enrollment to complete mid-2024, data Q1 2025.","Stage 1 of COMPANION-003 (CRC) enrollment complete; top-line data expected by mid-2024.","CTX-8371 first patient dosed in April 2024; Phase 2 planned for CTX-471 in melanoma with biomarker."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002784","json":"https://secwatch.observer/filing/0001171843-24-002784.json","markdown":"https://secwatch.observer/filing/0001171843-24-002784.md","text":"https://secwatch.observer/filing/0001171843-24-002784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324002784/0001171843-24-002784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324002784/f8k_051124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:31:12.060598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dec44a27a9a6dbed55d9d9e69ab875f594aa1499","claim":"Compass Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $10.8 million, EPS $0.08 per share of common stock.","evidence_excerpt":"On May 13, 2024, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324002784/0001171843-24-002784-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$10.8 million"},{"label":"EPS","value":"$0.08 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}